Cargando…
Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment
Aberrant cell cycle machinery and loss of the CDKN2A tumor suppressor locus make CDK4/6 a potential target in pancreatic ductal adenocarcinoma (PDAC). However, a vast majority of PDAC cases do not harbor a durable response to monotherapy of CDK4/6 inhibitor. Utilizing remote loading to co-encapsulat...
Autores principales: | Ji, Ying, Liu, Xiangsheng, Li, Juan, Xie, Xiaodong, Huang, Max, Jiang, Jinhong, Liao, Yu-Pei, Donahue, Timothy, Meng, Huan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447818/ https://www.ncbi.nlm.nih.gov/pubmed/32843618 http://dx.doi.org/10.1038/s41467-020-17996-7 |
Ejemplares similares
-
Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1
por: Liu, Xiangsheng, et al.
Publicado: (2021) -
Transcytosis - An effective targeting strategy that is complementary to “EPR effect” for pancreatic cancer nano drug delivery
por: Liu, Xiangsheng, et al.
Publicado: (2019) -
Integrity of lipid nanocarriers in bloodstream and tumor quantified by near-infrared ratiometric FRET imaging in living mice
por: Bouchaala, Redouane, et al.
Publicado: (2016) -
Use of Stromal Intervention and Exogenous Neoantigen Vaccination to Boost Pancreatic Cancer Chemo-Immunotherapy by Nanocarriers
por: Chattopadhyay, Saborni, et al.
Publicado: (2023) -
CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy
por: Nardone, Valerio, et al.
Publicado: (2021)